5 nurses who work on the same floor at Massachusetts hospital have brain tumors
A Boston-area hospital is investigating after five nurses who have worked on the same floor have developed brain tumors.
Mass General Brigham Newton-Wellesley Hospital said that in total, 11 employees from the fifth-floor maternity unit identified health concerns. Five had brain tumors, all of which are benign. Two of those have the most common, benign type — meningioma, according to the hospital in Newton, Massachusetts, which is about 10 miles west of Boston.
'The investigation found no environmental risks which could be linked to the development of a brain tumor,' the hospital's Jonathan Sonis, associate chief medical officer, and Sandy Muse, chief nursing officer, said in a statement.
The hospital said its investigation was completed in collaboration with government health and safety officials and it considered multiple possible sources. It ruled out disposable masks, the water supply, nearby x-rays, and chemotherapy treatment on the floor below, the hospital said.
'Based on these results, we can confidently reassure our dedicated team ... and all our patients that there is no environmental risk at our facility," the administrators said.
The Massachusetts Nurses Association, the union that bargains for nurses' compensation at Newton-Wellesley Hospital, said it will continue to investigate.
"Right now, the best way we can help is to complete an independent, scientific investigation," MNA spokesperson Joe Markman said in a statement Friday. "That effort is underway and may take additional weeks."
The union indicated that nurses came forward with workplace health concerns, which led to the discovery of those with tumors.
'The hospital only spoke to a small number of nurses, and their environmental testing was not comprehensive,' he said in his statement. 'The hospital cannot make this issue go away by attempting to provide a predetermined conclusion.'
A spokesperson for a state agency was unable to provide conclusive information on the matter by deadline. Federal occupational health and safety officials did not immediately respond to a request for comment.
The American Cancer Society says that in order to meet the definition of a cancer cluster, occurrences must be the same type, in the same area, with the same cause, and affecting a number of people that's "greater than expected" when a baseline for occurrences is established.
'Nearly 4 out of 10 people in the United States will develop cancer during their lifetimes," the society said on its cancer clusters webpage. "So, it's not uncommon for several people in a relatively small area to develop cancer around the same time."
This article was originally published on NBCNews.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Boston Medflight hosts heartwarming annual event that reunites patients with their caretakers
Boston MedFlight staff were reunited with the patients they served in their most critical and vulnerable moments. Boston MedFlight celebrates its 40th year of service, and with this annual event, it helps bring heartwarming moments for families and patients to reunite with the aviation members who cared for them in their most critical moments. Christine Muszalsk, a registered nurse who started the event back in 2001, says it's important to pause and acknowledge this work. 'A day like this is a reminder of how fragile life is and how important the work is that we do to help our patients.' Boston MedFlight is a non-profit organization that provides millions of dollars every year in free and unreimbursed care to patients with little or no medical insurance. This is a developing story. Check back for updates as more information becomes available. Download the FREE Boston 25 News app for breaking news alerts. Follow Boston 25 News on Facebook and Twitter. | Watch Boston 25 News NOW
Yahoo
6 hours ago
- Yahoo
Nearly 1400 people took part in national ‘Walk MS 2025′
Despite a rainy weekend, the weather certainly held out long enough for 'Walk MS 2025.' It's part of a national annual event that raises awareness and funds for the fight against multiple sclerosis. In Boston, participants walked along a one to three-mile route, overlooking the harbor, before finishing up at the UMass Boston campus. Multiple Sclerosis is a disease that affects a person's nervous system. Symptoms can often vary from person to person, including numbness and tingling to mobility challenges, blindness, and paralysis. Multiple Sclerosis affects an estimated 1 million people in the United States. Lori Espino, President of the National MS Society Greater New England Chapter, reflected on the walk. 'We had close to 1400 people come out either supporting a loved one with MS or living with MS themselves, and we raised over half a million dollars for a cure.' Sunday's walk was the sixth held in Massachusetts over the past few months; together, they've raised nearly one million dollars in donations. This is a developing story. Check back for updates as more information becomes available. Download the FREE Boston 25 News app for breaking news alerts. Follow Boston 25 News on Facebook and Twitter. | Watch Boston 25 News NOW
Yahoo
15 hours ago
- Yahoo
Ontada Unveils Comprehensive Data on Social Determinants of Health and Outcomes of Early-Onset Colorectal Cancer at ASCO
Findings show Black and Hispanic Patients Have 30% Higher Risk of Advanced-Stage Diagnosis BOSTON, May 30, 2025--(BUSINESS WIRE)--Ontada®, a leader in real-world oncology data and insights, is proud to present its latest research findings in a pivotal oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. The study, titled, "Real-world Social Determinants of Health and Outcomes of Early-onset Colorectal Cancer: An Analysis of a Large Nationally Representative US Community Oncology Network," provides critical data on the impact of social determinants on the outcomes of early-onset colorectal cancer (EO-CRC) patients, and offers one of the largest studies of EO-CRC to date. Over 104,000 patients with CRC were studied, including nearly 15,000 patients with early-onset CRC. Key Data Findings Racial and ethnic disparities: A higher burden of EO-CRC was observed among patients of Black and American Indian/Alaskan Native race and Hispanic/Latino ethnicity. Obesity as a risk factor: There was a 5% higher prevalence of obesity among patients with early-onset CRC versus average onset CRC. More advanced stage at diagnosis for EO-CRC: Patients with EO-CRC have an 11% greater likelihood of diagnosis at Stage III or IV disease as compared to average-onset disease. Poorer survival associated with advancing age: At each cancer stage, patients with EO-CRC had a longer overall survival as compared to patients with average-onset CRC, reflecting existing knowledge about cancer survival decreasing with advancing age. Importance of screening and earlier diagnosis: Among all patients with CRC, including early-onset diagnosis, disease stage at diagnosis was the strongest predictor of overall survival, reflecting the importance of earlier detection and screening programs for all. "Understanding the complex interplay between social factors and cancer incidence and outcomes is crucial for developing effective, patient-centered care strategies, and this research underscores the importance of understanding and then intervening on social determinants of health to improve care for patients with EO-CRC," said Jessica K. Paulus, ScD, senior director, Real-World Research, Ontada. "Ontada's data provides a clear and compelling picture of the impact of social determinants on the outcomes of patients with EO-CRC. By leveraging our unique data emanating from the nationally representative The US Oncology Network and our measures of social determinants at scale, we can drive meaningful changes in clinical practice and policy, ultimately improving patient care and outcomes." Study Methodology This retrospective observational cohort study examined adult CRC patients within The US Oncology Network and non-Network practices, encompassing over 2,700 community-based providers treating more than 1.4 million patients annually. All patients diagnosed with CRC between 2000 and 2024 were included; patients were categorized as EO-CRC if they were <50 years at first diagnosis and average-onset (AO)-CRC otherwise. Over 104,000 patients with CRC were studied, including nearly 15,000 patients with early-onset CRC. Patient characteristics were sourced from iKnowMed, an oncology-specific electronic health record system, and descriptively summarized. Overall Survival (OS) was assessed from diagnosis using Kaplan-Meier methods. Other Research at ASCO 2025 Ontada is showcasing its research capabilities at ASCO with 12 accepted abstracts on topics such as using large language models to extract cancer data, accelerating Phase 2 clinical development with real-world data in HER2-positive metastatic breast cancer, validating real-world event-free survival in early-stage triple negative breast cancer, analyzing outcomes of BRAF-mutated melanoma patients, and providing a descriptive epidemiology of Waldenström Macroglobulinemia. "At Ontada, we are at the forefront of transforming cancer care through the power of real-world data and insights," said Christine Davis, president, Ontada. "Our extensive research at ASCO 2025 underscores our commitment to driving meaningful advancements in oncology. This research will not only highlight the critical role of real-world evidence in improving patient outcomes but also demonstrate our dedication to addressing the complex challenges faced by cancer patients and healthcare providers." Ontada is a part of McKesson, which has an unmatched portfolio of oncology businesses and partners that provide research, insights, technologies, and services that are helping address barriers and improve cancer and specialty care. At ASCO, McKesson-supported businesses including The US Oncology Network, Ontada, and Sarah Cannon Research Institute (SCRI), are part of approximately 170 accepted abstracts and presentations. These are inclusive of oral and poster presentations, educational sessions, late-breaking studies, and early-phase studies. For a comprehensive list of Ontada abstracts and presentations, visit Ontada's ASCO 2025 Site. Additionally, visit the Ontada Booth (#35093) at the McCormick Place Convention Center from May 30 – June 3 to explore the data presented at ASCO 2025 and experience Ontada's solutions firsthand. About Ontada® Ontada is an oncology technology and insights business dedicated to transforming the fight against cancer. Part of McKesson Corporation, Ontada was founded on the core belief that precise insights – delivered exactly at the point of need – can save more patients' lives. We connect the full patient journey by combining technologies used by The US Oncology Network and other community oncology providers with real-world data and research relied on by all top 15 global life sciences companies. Our work helps accelerate innovation and powers the future of cancer care. For more information, visit About McKesson Oncology and Specialty Solutions It's an unprecedented time for patients living with cancer as life sciences companies race to create new, cutting-edge therapies. With cancer care becoming more targeted, providers, life sciences companies, and payers face a multitude of challenges and complexity in the development of new treatments and making them accessible to patients in need. At McKesson, our unmatched portfolio of oncology businesses and partners provide research, insights, technologies, and services that are helping to address these hurdles and improve cancer and specialty care. McKesson is fueling discovery by helping patients participate in cutting-edge clinical trials closer to home through its joint venture with Sarah Cannon Research Institute. The US Oncology Network and McKesson Provider Solutions are advancing specialty care and high-quality cancer care in the communities where patients live by supporting the practices of thousands of independent, community-based providers. Ontada®, a McKesson business dedicated to oncology, generates real-world data (RWD) and real-world evidence (RWE), and provides clinical education and provider technology to inform and improve cancer care. As a leading distributor of oncology and specialty medicines, we are ensuring medicines make their way to those who are counting on them. And through CoverMyMeds, Biologics by McKesson, and GPO services, our work continues to help patients access, afford, and adhere to their medicines. View source version on Contacts Media Contact OntadaClaire Crye, Communications281.825.9927 GCI Health on behalf of OntadaChristine Murphy, Media Relations201.230.9636 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data